Old Web
English
Sign In
Acemap
>
authorDetail
>
William A. Palo
William A. Palo
TAP Pharmaceutical Products
Medicine
Internal medicine
Surgery
Gout
Hyperuricemia
5
Papers
1302
Citations
0.01
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Tophaceous gout: quantitative evaluation by direct physical measurement.
2005
The Journal of Rheumatology
H. Ralph Schumacher
Michael Becker
William A. Palo
Janet Streit
Patricia A. MacDonald
Nancy Joseph-Ridge
Show All
Source
Cite
Save
Citations (39)
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
2005
Arthritis & Rheumatism
Michael Becker
H. Ralph Schumacher
Robert L. Wortmann
Patricia A. MacDonald
William A. Palo
Denise Eustace
Laurent Vernillet
Nancy Joseph-Ridge
Show All
Source
Cite
Save
Citations (228)
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
2005
The New England Journal of Medicine
Michael Becker
H Ralph
Robert L. Wortmann
Patricia A. MacDonald
Denise Eustace
William A. Palo
Janet Streit
Nancy Joseph-Ridge
Show All
Source
Cite
Save
Citations (985)
Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: Results of a multicenter, prospective, randomized, double-blind study
2002
Clinical Therapeutics
Louis Van Zyl
Jacobus G. Le Roux
John A. Lafata
R. Scott Volk
William A. Palo
Robert Flamm
Richard C. Hom
Show All
Source
Cite
Save
Citations (22)
A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study.
2002
Clinical Therapeutics
Charles M. Fogarty
Marcia Cyganowski
William A. Palo
Richard C. Hom
William A. Craig
Show All
Source
Cite
Save
Citations (28)
1